Business Context and Reporting Period
This Form 8-K Current Report was filed by Aileron Therapeutics, Inc. (trading symbol: ALRN) on June 24, 2019, reporting events that occurred on June 19, 2019. The company is an emerging growth company incorporated in Delaware with principal executive offices in Watertown, MA. The filing primarily addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on director appointments and associated compensation arrangements rather than operational financial performance.
Material Changes
The material change reported is the election of two new directors to the Board of Directors, effective June 19, 2019:
- William T. McKee: Elected as a Class II director (term expiring 2022) and appointed Chairman of the Audit Committee.
- Josef H. von Rickenbach: Elected as a Class III director (term expiring 2020).
Both directors received pro-rated annual cash fees and stock options as part of their appointment.
Compensation and Governance Details
Under the Company's director compensation program, the following arrangements were established for the new directors:
- Cash Fees: Each director receives a pro-rated annual cash fee of $35,000. Mr. McKee receives an additional pro-rated fee of $22,500 for serving as Audit Committee Chairman. Fees are payable in arrears quarterly.
- Stock Options: Each director was granted an option to purchase 25,000 shares of common stock at an exercise price of $0.86 per share. These options vest in three equal annual installments starting June 19, 2019, and become fully exercisable upon a change of control.
- Indemnification: Both directors entered into standard indemnification agreements, potentially requiring the Company to cover legal expenses, judgments, and fines arising from their service.
Investor Verification Checklist
- Verify the current share price relative to the $0.86 exercise price of the newly granted director options.
- Review the Company's most recent 10-K or 10-Q filings for actual revenue, cash burn, and liquidity positions, as this 8-K does not contain them.
- Confirm the total number of outstanding shares to assess the dilution impact of the 50,000 new options granted.
- Check for any subsequent filings regarding the status of the Audit Committee or other board committee assignments.